

COVID 19 Outpatient Treatment Tier Level

Premier is currently evaluating outpatients at Tier 4 for Paxlovid and Bebtelovimab.

Due to limited drug availability Premier Health is prioritizing patients who are most at risk for hospitalization and severe disease secondary to COVID-19. We will be following the National Institutes of Health's (NIH's) interim patient prioritization guidance, as shown below.

Tier	Risk Group
1	<ul style="list-style-type: none">Immunocompromised individuals not expected to mount an adequate immune response to COVID-19 vaccination or SARS-CoV-2 infection due to their underlying conditions, regardless of vaccine status (see Immunocompromising Conditions below); <i>or</i>Unvaccinated individuals at the highest risk of severe disease (anyone aged ≥75 years or anyone aged ≥65 years with additional risk factors).
2	<ul style="list-style-type: none">Unvaccinated individuals at risk of severe disease not included in Tier 1 (anyone aged ≥65 years or anyone aged <65 years with clinical risk factors)
3	<ul style="list-style-type: none">Vaccinated individuals at high risk of severe disease (anyone aged ≥75 years or anyone aged ≥65 years with clinical risk factors) <p>Note: Vaccinated individuals who have not received a COVID-19 vaccine booster dose are likely at higher risk for severe disease; patients in this situation within this tier should be prioritized for treatment.</p>
4	<ul style="list-style-type: none">Vaccinated individuals at risk of severe disease (anyone aged ≥65 years or anyone aged <65 with clinical risk factors) <p>Note: Vaccinated individuals who have not received a COVID-19 vaccine booster dose are likely at higher risk for severe disease; patients in this situation within this tier should be prioritized for treatment.</p>